Stanford Researchers Discover BRP Peptide — A Potential Side-Effect-Free Alternative to Ozempic
Stanford scientists have identified a novel brain-targeted peptide called BRP that suppresses appetite as effectively as GLP-1 drugs but without nausea or muscle loss in animal models.
Source: ScienceDaily
GLP-1 Drugs Show Promise for Addiction Treatment in Emerging Research
Harvard researchers outline expanding clinical applications for GLP-1 peptides beyond weight loss, including early evidence of reduced cravings in substance use disorders.
Source: Harvard Gazette
Mitochondrial Peptides Emerge as Major Research Category in 2026
MOTS-C and humanin are moving from niche curiosities to recognized research targets, with new studies exploring their roles in aging, metabolism, and exercise mimicry.
Source: Alpha Peptides
Novartis Wins Expanded FDA Approval for Peptide-Based Prostate Cancer Therapy Pluvicto
Pluvicto (lutetium-177 vipivotide tetraxetan) receives expanded approval for use before chemotherapy in metastatic prostate cancer, showing a 28% reduction in disease progression risk.
Source: Peptide Protocol Wiki
Genetic Study Reveals 10% of Population May Be Resistant to GLP-1 Diabetes Drugs
Stanford researchers have identified genetic variants carried by roughly one in ten people that significantly reduce the effectiveness of GLP-1 receptor agonists for blood sugar control.
Source: Stanford Medicine
Eli Lilly's Retatrutide Delivers Record 71-Pound Average Weight Loss in Phase 3 Trial
The triple-agonist peptide retatrutide achieved unprecedented weight loss in the TRIUMPH-4 trial while also providing substantial relief from osteoarthritis knee pain.
Source: Eli Lilly Investor Relations
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.